8th Great Lakes Nuclear Receptor Conference Program
October 18 - 19, 2018 | Minneapolis, Minnesota

Thursday October 18

2:00 PM Check in and poster set up
4:15 - 4:30 PM Welcome and opening remarks
4:30 - 5:30 PM Opening Keynote:
Bone and behaviors regulated by sex-dependent estrogen-responsive neural circuits
Holly Ingraham, PhD, University of California, San Francisco

5:30 - 6:30 PM Talks in Hot Topics (selected from abstracts)
Estrogen receptor beta elicits anti-cancer effects in TNBC cancer through suppression of NFkB signaling
Kirsten Aspros, Mayo Clinic
Deciphering the Regulome of Androgen Receptor Variants in Prostate Cancer
Mark Daniel, University of Minnesota, Twin Cities
Small Heterodimer Partner Lowers Breast Cancer Progression through Its Immunomodulatory Role in Macrophages, Blocking Regulatory T Cell Responses
Sayyed Hamed, University of Illinois at Urbana-Champaign
Phosphorylated progesterone receptor isoforms mediate opposing stem-like and proliferative breast cancer cell fates
Thu Truong and Amy Dwyer, University of Minnesota, Twin Cities

6:45 - 8:15 PM Dinner (on site)

Friday, October 19

7:30 - 8:30 AM Breakfast and poster set up
8:30 - 9:05 AM Special seminar and discussion:
Promoter-selective androgen receptor modulation
Diane Robins, PhD, University of Michigan, Ann Arbor

Session 1: Hormone driven cancers
Session chairs: Charles Clevenger, MD, PhD, Virginia Commonwealth University, Elaine Alarid, PhD, University of Wisconsin, Madison

9:05 - 9:20 AM Molecular imaging approaches for tailored treatment of ER+ breast cancer
Amy Fowler, MD, PhD, University of Wisconsin, Madison

9:20 - 9:35 AM Cholesterol metabolism, nuclear receptors, immune cells and cancer progression
Erik Nelson, PhD, University of Illinois at Urbana-Champaign

9:35 - 9:50 AM Metabolic reprogramming by steroid receptor coactivator drives metastatic breast cancers
Subhamoy Dasgupta, PhD, Roswell Park Comprehensive Cancer Center

9:50 - 10:05 AM Discussion

10:05 - 10:25 AM Break (Refreshments Provided)
Friday, October 19 continued

**Session 2: Nuclear Receptor cofactors in hormone-dependent cancers**
Session chairs: Marja Nevalainen, MD, PhD, Medical College of Wisconsin, Michel Sanders, University of Minnesota, Twin Cities

10:25 - 10:40 AM  
PELP1 and SRC-3 complexes promote cancer stem cell associated phenotypes in ER+ breast cancer models  
Julie Ostrander, PhD, University of Minnesota, Twin Cities

10:40 - 10:55 AM  
NFIB differentially regulates AR in primary and castrate resistant prostate cancer  
Magdalena Grabowska, PhD, Case Western Reserve University

10:55 - 11:10 AM  
Targeted protein degrader-compounds as therapeutics for castration-resistant prostate cancer  
Steve Kregel, PhD, University of Michigan

11:10 - 11:25 AM  
Discussion

**Session 3: Nuclear receptors in a development and disease**
Session chairs: Gail Prins, PhD, University of Illinois at Chicago, Paul Mermelstein, PhD, University of Minnesota- Twin Cities

11:25 - 11:40 AM  
Nuclear receptors and gene-environment effect on gene regulation  
Francesca Luca, PhD, Wayne State University

11:40 - 11:55 AM  
Role of CDK7 and SF1 in adrenocortical cell proliferation and stem cell renewal  
Yewei Xing, PhD, University of Michigan

11:55 AM - 12:10 PM  
Estrogen receptor activation in BPH  
Teresa Liu, PhD, University of Wisconsin, Madison

12:10 - 12:25 PM  
Discussion

12:25 - 1:30 PM  
Lunch provided onsite

**Session 4: Nuclear receptors in metabolism and immunity**
Session chairs: Carol Lange, PhD, University of Minnesota, Twin Cities, Kaylee Schwertfeger, PhD, University of Minnesota, Twin Cities

1:30 - 1:45 PM  
Genetics of gene regulation by PPAR nuclear receptors in cardiometabolic disease  
Raymond Soccio, MD, PhD, University of Pennsylvania

1:45 - 2:00 PM  
PPARα mediates the lipid-reducing action of bilirubin  
Terry Hinds, Jr., PhD, The University of Toledo

2:00 - 2:15 PM  
Targeting steroid hormone receptor pathways to improve anti-tumor immunity  
Laura Stabile, PhD, University of Pittsburgh

2:15 - 2:30 PM  
Discussion

2:30 - 4:00 PM  
Poster Session and refreshments

4:00 - 5:00 PM  
Closing Keynote:  
Mechanisms driving persistent androgen receptor activity in castration resistant prostate cancer  
Steven Balk, MD, PhD, Beth Israel Deaconess Medical Center

5:00 - 6:00 PM  
Closing remarks, awards, and reception

6:30 PM  
Depart for dinner with small groups (optional)